Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STAA
STAA logo

STAA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy STAAR Surgical Co (STAA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
29.140
1 Day change
-0.27%
52 Week Range
35.870
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

STAA is not a clear buy right now for a Beginner long-term investor with $50,000-$100,000 who is impatient and wants a direct entry. The recent analyst sentiment has improved meaningfully and the Q1 rebound, especially in China, is encouraging, but the stock is still trading below the pivot with weakening momentum and no fresh catalyst in the past week. My direct view: hold rather than buy today.

Technical Analysis

Pre-market price is 28.9, which is slightly below the pivot of 29.497 and just above support at 28.343. MACD histogram is -0.428 and still negatively expanding, which points to weak near-term momentum. RSI_6 at 35.829 is neutral but leaning soft. Moving averages are converging, which often signals a potential inflection, but not yet a confirmed uptrend. Overall, the chart is constructive but not strong enough to call it a clean buy at this moment.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is clearly bullish. The open interest put-call ratio of 0.42 and option volume put-call ratio of 0.02 indicate calls heavily dominate puts, suggesting traders are positioning for upside. IV rank at 24.53 and IV percentile at 36.51 are moderate, so options are not excessively priced. However, today's volume is very light versus open interest, so the options signal is supportive but not a strong standalone trigger.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
5

Positive Catalysts

  • ["Q1 results were well ahead of expectations.", "China business was especially strong, with revenue of $47.4M driven by underlying demand.", "Several analysts raised price targets after the Q1 print.", "Wedbush upgraded the stock to Outperform and sees a potential China rebound inflection point.", "Canaccord upgraded to Buy and cited strong progress in China and attractive valuation.", "Sentiment suggests shares may trade well on the improved operating picture."]

Neutral/Negative Catalysts

  • ["No guidance was issued, so visibility remains limited.", "The stock is still below the pivot and momentum indicators are not yet confirming a breakout.", "No news in the recent week, so there is no immediate event-driven catalyst.", "Hedge funds and insiders are neutral, showing no strong accumulation signal.", "No recent congress trading activity was reported."]

Financial Performance

Latest quarter: Q1 2026. Financial commentary indicates the quarter beat expectations on both top and bottom line, with preliminary net sales above $90M. China was the main driver, and Americas growth remained in double digits. Management did not provide FY26 revenue guidance, which limits visibility even though the underlying growth trend in the latest quarter was strong.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has improved notably in the latest round. Wedbush upgraded STAA to Outperform with a $40 target, Canaccord upgraded to Buy with a $32 target, Piper Sandler raised its target to $33 and stayed Neutral, Stifel raised its target to $31 and stayed Hold, and Mizuho raised its target to $27 but kept Neutral. The Wall Street pros view is mixed but improving: bulls focus on a possible China rebound and valuation re-rating, while bears remain cautious because management gave no guidance and visibility is still limited.

Wall Street analysts forecast STAA stock price to rise
3 Analyst Rating
Wall Street analysts forecast STAA stock price to rise
0 Buy
3 Hold
0 Sell
Hold
Current: 29.220
sliders
Low
30.75
Averages
30.75
High
30.75
Current: 29.220
sliders
Low
30.75
Averages
30.75
High
30.75
Mizuho
Anthony Petrone
Neutral
maintain
$22 -> $27
AI Analysis
2026-05-14
Reason
Mizuho
Anthony Petrone
Price Target
$22 -> $27
AI Analysis
2026-05-14
maintain
Neutral
Reason
Mizuho analyst Anthony Petrone raised the firm's price target on Staar Surgical to $27 from $22 and keeps a Neutral rating on the shares. The company's Q1 results were well ahead of expectations, the analyst tells investors in a research note. However, the firm says no guidance was issued as visibility still remains limited.
Wedbush
Neutral
to
Outperform
upgrade
$26 -> $40
2026-05-14
Reason
Wedbush
Price Target
$26 -> $40
2026-05-14
upgrade
Neutral
to
Outperform
Reason
Wedbush upgraded Staar Surgical to Outperform from Neutral with a price target of $40, up from $26. The Q1 report brings confidence that Staar is either at or nearing an inflection point for a full China rebound, the analyst tells investors in a research note. Wedbush says it is taking a longer-term view to the Staar Surgical story. It would \"rather be early than late\" as the firm believes the company has the potential to exceed even its bull case scenario in the coming quarters. Further China recovery progress is likely to lead to valuation re-rating and multiple expansion to historical levels, Wedbush contends.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STAA
Unlock Now

People Also Watch